News
🇪🇺 EuropeLatest pharmaceutical news, drug approvals, and EMA regulatory updates
Latest News
EMA Recommends First Bispecific T-Cell Engager for Relapsed Small Cell Lung Cancer
European regulators back Amgen's Imdylltra as breakthrough treatment for extensive-stage SCLC, marking first BiTE therapy approval in solid tumors.
EMA Advances Virtual Control Groups to Reduce Animal Testing in Drug Development
European Medicines Agency issues draft qualification opinion on new methodology that could significantly reduce animal use in preclinical research.
AI in European Pharmaceutical R&D: Investment & Regulatory Insights
This article delves into the transformative impact of AI on European pharmaceutical R&D, focusing on investment trends and regulatory challenges in drug development.
EMA Accelerated Assessment of Novel mRNA Vaccine Platforms for Pandemic Preparedness
The EMA is fast-tracking the evaluation of innovative mRNA vaccine platforms to bolster pandemic preparedness and improve responses to infectious diseases.
Gene Therapies for Neurological Disorders: EMA Approval Trends & Insights
This article delves into the latest EMA approval trends for gene therapies, focusing on Zolgensma and its impact on neurological disorder treatments.
EU Clinical Trials Regulation 2026: Impact on Rare Disease Drug Development
The EU Clinical Trials Regulation 2026 aims to streamline processes, significantly influencing the development of drugs for rare diseases such as Duchenne Muscular Dystrophy.
Blockchain in Pharmaceutical Supply Chain: EMA's Role in Traceability & Anti-Counterfeiting
This article delves into the EMA's pivotal role in utilizing blockchain technology to enhance traceability and combat counterfeiting in the pharmaceutical supply chain.
GDPR Impact on Pharmaceutical Data: What You Need to Know
Explore the implications of GDPR on pharmaceutical data handling, focusing on compliance challenges and best practices for drugs like Lipitor.
AI-Powered Clinical Trial Matching: Transforming Patient Recruitment in the EU
AI-powered clinical trial matching is transforming patient recruitment in the EU, streamlining access to groundbreaking treatments for chronic diseases.
Digital Therapeutics in Europe: Market Trends and EMA Regulatory Insights
This article delves into the evolving landscape of digital therapeutics in Europe, highlighting market trends and regulatory insights from the EMA for effective treatment solutions.
MHRA post-Brexit regulatory pathway vs EMA: Strategic Guide 2024
This strategic guide compares the MHRA and EMA regulatory pathways post-Brexit, focusing on drug approval processes for 2024.
Orphan Drug Pricing EU: Market Analysis and Reimbursement Trends
This article analyzes orphan drug pricing in the EU, examining market dynamics and reimbursement trends for treatments like Spinraza in rare diseases.
EU Pharmaceutical Strategy: Impact on API Manufacturing in Europe
The EU Pharmaceutical Strategy aims to strengthen API manufacturing in Europe, ensuring a stable supply of essential drugs for chronic disease management.
EU Pharmaceutical Legislation Reform: Impact on Market Access & Innovation
The EU Pharmaceutical Legislation Reform aims to enhance market access and foster innovation, significantly affecting drug availability and patient care.
Denosumab Biosimilar Authorization by EMA: Key Details
The EMA has authorized Denosumab biosimilars, marking a significant advancement in osteoporosis treatment and improving patient access to effective therapies.
CHMP Positive Opinion CAR-T Therapy: What You Need to Know
The CHMP has issued a positive opinion for CAR-T therapy, a groundbreaking treatment for specific blood cancers, offering new hope for patients.
EU Pharmaceutical Legislation Reform: Impact on Biopharma Innovation
The EU Pharmaceutical Legislation Reform aims to enhance biopharma innovation, influencing drug development processes for critical therapies like Xyrem.
EMA Releases Landmark Guidelines on AI Use in Clinical Trials
The EMA has unveiled landmark guidelines on the use of AI in clinical trials, paving the way for improved drug development and patient outcomes.